Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Liabilities (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Total Liabilities for 17 consecutive years, with $161.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 37.48% to $161.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $161.8 million through Dec 2025, up 37.48% year-over-year, with the annual reading at $161.8 million for FY2025, 37.48% up from the prior year.
  • Total Liabilities hit $161.8 million in Q4 2025 for Vanda Pharmaceuticals, up from $135.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $161.8 million in Q4 2025 to a low of $75.6 million in Q1 2021.
  • Historically, Total Liabilities has averaged $108.0 million across 5 years, with a median of $105.0 million in 2022.
  • Biggest five-year swings in Total Liabilities: fell 7.19% in 2023 and later skyrocketed 37.48% in 2025.
  • Year by year, Total Liabilities stood at $88.9 million in 2021, then increased by 20.46% to $107.0 million in 2022, then dropped by 3.29% to $103.5 million in 2023, then grew by 13.65% to $117.7 million in 2024, then soared by 37.48% to $161.8 million in 2025.
  • Business Quant data shows Total Liabilities for VNDA at $161.8 million in Q4 2025, $135.1 million in Q3 2025, and $138.4 million in Q2 2025.